Shares of the company are trading at $663.85 which is slightly above $567.30, the 50 day moving average and barely above the 200 day moving average of $505.50. The 50 day moving average moved up $96.55 and the 200 day average was up $158.35. Trading volume for Atrion Corporation was 14K by the end of trading on Thursday. Volume was up 187.43% over the stocks average daily volume.
Traders are a little more bullish on the company as shown by the fall in short interest. The company recorded a fall in short interest of -3.98% as of the latest report on May 31, 2017. Short interest decreased 887 over that timeframe. The days to cover decreased to 3.6 and the percentage of shorted shares was 0.01% on May 31.
There has been some selling insider activity on Atrion Corporation (NASDAQ:ATRI) recently. Emile A. Battat, Chairman let go of $406,811 worth of shares at a price of $581.99 on June 6th. That brings the Chairman’s holdings to $86,705,452 as recorded in a recent Form 4 SEC filing. Emile A. Battat, Chairman sold $684,416 worth of shares at a price of $562.38 on Fri the 2nd. The Chairman now owns $84,177,038 of the stock per an SEC filing yesterday.
CFO Jeffery Strickland sold 1,000 shares at a price of $510.18 on Mon the 19th. That brings Strickland’s holdings to $1,595,333 as reported to the SEC.
These funds have also shifted positions in (ATRI). As of the end of the quarter Morgan Stanley had sold 15 shares trimming its holdings by 100.0%. The value of the investment in ATRI decreased from $8,000 to $0 decreasing 100.0% quarter over quarter. As of quarter end Tower Research Capital LLC (trc) had acquired a total of 16 shares growing its stake by 114.3%. The value of the investment in (ATRI) went from $7,000 to $14,000 a change of 100.0% quarter to quarter.
As of quarter end Goldman Sachs Group Inc had disposed of 181 shares trimming its position 6.8%. The value of the company’s investment in Atrion Corporation decreased from $1,346,000 to $1,157,000 a change of $189,000 since the last quarter. As of quarter end Schroder Investment Management Group had acquired 145 shares growing its stake by 30.1%. The value in dollars increased from $244,000 to $293,000 increasing 20.1% for the reporting period.
Equity analyst BWS Financial began coverage giving it an initial rating of “Sell” and establishing a price target of $300.00.
The company is down by -2.55 percent from yesterday’s close. The company recently announced a dividend which was paid on Friday June 30th, 2017. The dividend payment was $1.050 per share for the quarter or $4.20 on an annualized basis. The dividend yield was $0.63. The ex-dividend date was Tuesday the 13th of June 2017.
The company currently has a P/E ratio of 40.31 and the market value is 1.22B.
Atrion Corporation (Atrion), launched on December 30, 1996, is involved in developing and manufacturing products, primarily for medical applications. The Business’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology..